ANTI-HMGB1 antibody

2 papers1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: Deutsches Zentrum für Neurodegenerative Erkrankungen and 5 more

Cells1

Outcomes

Cellular senescence

downin human cells1

1 study

ANTI-HMGB1 antibody decreases cellular senescence in human cells.
“Strikingly, HMGB1 neutralization enhances hepatocyte viability and mitigates senescence, underscoring its pathogenic role.”
Cellsin hiPSC-Heps under in vitro IRI condition
iRhom2 regulates HMGB1 secretion to modulate inflammation and hepatocyte senescence in an in vitro model of ischemia-reperfusion injury
Cell death & disease7 Jan 2026